SuperworthAgios Pharmaceuticals EPS AGIO
Diluted earnings per share by quarter and over the last twelve months, from 2012.
- Last 12 months, to Jun 30, 2026
- −$7.01
- Latest quarter, Q2 FY26
- −$1.69
- Fiscal year 2025
- −$7.11
- −162% on the year before
Agios Pharmaceuticals' earnings per share was −$7.01 over the twelve months to Jun 30, 2026, down 163% on a year earlier.
In its latest quarter, Q2 FY26, it was −$1.69.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$7.11 | −162% |
| FY2024 | $11.39 | n/a |
| FY2023 | −$6.34 | n/a |
| FY2022 | −$4.25 | −119% |
| FY2021 | $22.24 | n/a |
| FY2020 | −$4.74 | n/a |
| FY2019 | −$6.87 | n/a |
| FY2018 | −$6.03 | n/a |
| FY2017 | −$6.74 | n/a |
| FY2016 | −$5.05 | n/a |
| FY2015 | −$3.13 | n/a |
| FY2014 | −$1.59 | n/a |
| FY2013 | −$6.19 | n/a |
| FY2012 | −$8.03 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.69 | n/a | −$7.01 | |
| Q1 FY26 | −$1.69 | n/a | −$7.25 | |
| Q4 FY25 | −$1.85 | n/a | −$7.11 | |
| Q3 FY25 | −$1.78 | −111% | −$6.95 | |
| Q2 FY25 | −$1.93 | n/a | $11.05 | |
| Q1 FY25 | −$1.55 | n/a | $11.29 | |
| Q4 FY24 | −$1.69 | n/a | $11.39 | |
| Q3 FY24 | $16.22 | n/a | $11.36 | |
| Q2 FY24 | −$1.69 | n/a | −$6.50 | |
| Q1 FY24 | −$1.45 | n/a | −$6.32 | |
| Q4 FY23 | −$1.72 | −361% | −$6.34 | |
| Q3 FY23 | −$1.64 | n/a | −$3.96 |
Against its peers
Companies in Drug Manufacturers - General nearest Agios Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| AGIOAgios Pharmaceuticals | −$7.01 | −163% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| NRIXNurix Therapeutics | $2.31 | |
| ANIPANI Pharmaceuticals | $4.70 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANABAnaptysbio | $4.57 | |
| PCRXPacira BioSciences | $0.35 | |
| OGNOrganon | $0.77 | −71% a year |
| LQDALiquidia | $1.39 | |
| ARQTArcutis Biotherapeutics | $0.22 | |
| Peer median | $2.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Agios Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.